Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05591222. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.
Study identification
- NCT ID
- NCT05591222
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2022 (Actual)
- Primary completion
- May 8, 2025 (Actual)
- Completion
- May 8, 2025 (Actual)
- Last update posted
- May 14, 2026
2022 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Research Trials | North Little Rock | Arkansas | 72117 | — |
| Wallace Medical Group | Beverly Hills | California | 90211 | — |
| The Center for Dermatology Clinical Research | Fremont | California | 94538 | — |
| Clinical Science Institute | Santa Monica | California | 90404 | — |
| Miami Dermatology & Laser Research | Miami | Florida | 33173 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| Detroit Clinical Research Center, PC | Farmington Hills | Michigan | 48334 | — |
| Michigan Dermatology Institute | Waterford | Michigan | 48328 | — |
| Minnesota Clinical Study Center | New Brighton | Minnesota | 55112 | — |
| MediSearch Clinical Trials | Saint Joseph | Missouri | 64506 | — |
| Forest Hills Dermatology | Forest Hills | New York | 11375 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Wright State Physicians | Fairborn | Ohio | 45324 | — |
| Paddington Testing Company, Inc. | Philadelphia | Pennsylvania | 19103 | — |
| Autoimmune Skin Diseases Unit, Dept. of Dermatology | Philadelphia | Pennsylvania | 19104 | — |
| Center for Clinical Studies (Cypress) | Houston | Texas | 77065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05591222, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.